The APOEɛ4 allele is the largest genetic risk factor for late-onset Alzheimer’s disease (AD). Recent literature suggested that the contribution of APOEɛ4 to AD risk could be population-specific, with ɛ4 conferring a lower risk to Blacks or African Americans.
Objective:
To investigate the effect of APOE haplotypes on AD risk in individuals with European ancestry (EU) and Blacks or African Americans (AA).
Methods:
We selected data from 1) the National Alzheimer’s Coordinating Center: a total of 3,486 AD cases and 4,511 controls (N = 7,997, 60% female) with genotypes from the Alzheimer’s Disease Genetics Consortium (ADGC), and 2) the Rush University Religious Orders Study and Memory and Aging Project (ROSMAP) cohort with 578 AD and 670 controls (N = 1,248, 60% female). Using ɛ3 homozygotes as the reference, we compared the association of various APOE haplotypes with the clinical and neuropathological correlates of dementia in AA and EU.
Results:
In both cohorts, we find no difference in the odds or age of onset of AD among the ɛ4-linked haplotypes defined by rs769449 within either AA or EU. Additionally, while APOEɛ4 was associated with a faster rate of decline, no differences were found in rate of decline, clinical or neuropathological features among the ɛ4-linked haplotypes. Further analysis with other variants near the APOE locus failed to identify any effect modification.
Conclusion:
Our study finds similar effects of the ɛ4-linked haplotypes defined by rs769449 on AD as compared to ɛ3 in both AA and EU. Future studies are required to understand the heterogeneity of APOE conferred risk of AD among various genotypes and populations.
Alzheimer’s Association (2019) 2019 Alzheimer’s disease facts and figures. Alzheimers Dement15, 321–387.
2.
MahleyRW, RallSCJr (2000) Apolipoprotein E: Far more than a lipid transport protein. Annu Rev Genomics Hum Genet1, 507–537.
3.
ShenL, JiaJ (2016) An overview of genome-wide association studies in Alzheimer’s disease. Neurosci Bull32, 183–190.
4.
CuyversE, SleegersK (2016) Genetic variations underlying Alzheimer’s disease: Evidence from genome-wide association studies and beyond. Lancet Neurol15, 857–868.
5.
LeeSH, HaroldD, NyholtDR, ANZGene Consortium; International Endogene Consortium; Genetic and Environmental Risk for Alzheimer’s disease Consortium, GoddardME, ZondervanKT, WilliamsJ, MontgomeryGW, WrayNR, VisscherPM (2013) Estimation and partitioning of polygenic variation captured by common SNPs for Alzheimer’s disease, multiple sclerosis and endometriosis. Hum Mol Genet22, 832–841.
RiedelBC, ThompsonPM, BrintonRD (2016) Age, APOE and sex: Triad of risk of Alzheimer’s disease. J Steroid Biochem Mol Biol160, 134–147.
8.
YamazakiY, ZhaoN, CaulfieldTR, LiuCC, BuG (2019) Apolipoprotein E and Alzheimer disease: Pathobiology and targeting strategies. Nat Rev Neurol15, 501–518.
9.
CorboRM, ScacchiR (1999) Apolipoprotein E (APOE) allele distribution in the world. Is APOE*4 a ‘thrifty’ allele?Ann Hum Genet63, 301–310.
10.
FarrerLA, CupplesLA, HainesJL, HymanB, KukullWA, MayeuxR, MyersRH, Pericak-VanceMA, RischN, van DuijnCM (1997) Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA278, 1349–1356.
11.
TangMX, SternY, MarderK, BellK, GurlandB, LantiguaR, AndrewsH, FengL, TyckoB, MayeuxR (1998) The APOE-epsilon4 allele and the risk of Alzheimer disease among African Americans, whites, and Hispanics. JAMA279, 751–755.
12.
RajabliF, FelicianoBE, CelisK, Hamilton-NelsonKL, WhiteheadPL, AdamsLD, BussiesPL, ManriqueCP, RodriguezA, RodriguezV, StarksT, ByfieldGE, Sierra LopezCB, McCauleyJL, AcostaH, ChineaA, KunkleBW, ReitzC, FarrerLA, SchellenbergGD, VardarajanBN, VanceJM, CuccaroML, MartinER, HainesJL, ByrdGS, BeechamGW, Pericak-VanceMA (2018) Ancestral origin of ApoE epsilon4 Alzheimer disease risk in Puerto Rican and African American populations. PLoS Genet14, e1007791.
13.
EvansDA, BennettDA, WilsonRS, BieniasJL, MorrisMC, ScherrPA, HebertLE, AggarwalN, BeckettLA, JoglekarR, Berry-KravisE, SchneiderJ (2003) Incidence of Alzheimer disease in a biracial urban community: Relation to apolipoprotein E allele status. Arch Neurol60, 185–189.
14.
KnopmanDS, MosleyTH, CatellierDJ, CokerLH, Atherosclerosis Risk in Communities Study Brain MRI Study (2009) Fourteen-year longitudinal study of vascular risk factors, APOE genotype, and cognition: The ARIC MRI Study. Alzheimers Dement5, 207–214.
15.
SawyerK, Sachs-EricssonN, PreacherKJ, BlazerDG (2009) Racial differences in the influence of the APOE epsilon 4 allele on cognitive decline in a sample of community-dwelling older adults. Gerontology55, 32–40.
16.
HendrieHC, MurrellJ, BaiyewuO, LaneKA, PurnellC, OgunniyiA, UnverzagtFW, HallK, CallahanCM, SaykinAJ, GurejeO, HakeA, ForoudT, GaoS (2014) APOE epsilon4 and the risk for Alzheimer disease and cognitive decline in African Americans and Yoruba. Int Psychogeriatr26, 977–985.
ZhangA, ZhaoQ, XuD, JiangS (2018) Brain APOE expression quantitative trait loci-based association study identified one susceptibility locus for Alzheimer’s disease by interacting with APOE epsilon4. Sci Rep8, 8068.
19.
LawsSM, HoneE, GandyS, MartinsRN (2003) Expanding the association between the APOE gene and the risk of Alzheimer’s disease: Possible roles for APOE promoter polymorphisms and alterations in APOE transcription. J Neurochem84, 1215–1236.
20.
BelbinO, DunnJL, LingY, MorganL, ChappellS, BeaumontH, WardenD, SmithDA, KalshekerN, MorganK (2007) Regulatory region single nucleotide polymorphisms of the apolipoprotein E gene and the rate of cognitive decline in Alzheimer’s disease. Hum Mol Genet16, 2199–2208.
21.
Bratosiewicz-WasikJ, LiberskiPP, PeplonskaB, StyczynskaM, Smolen-DzirbaJ, CyconM, WasikTJ (2018) Regulatory region single nucleotide polymorphisms of the apolipoprotein E gene as risk factors for Alzheimer’s disease. Neurosci Lett684, 86–90.
22.
ZhouX, ChenY, MokKY, KwokTCY, MokVCT, GuoQ, IpFC, ChenY, MullapudiN, Alzheimer’s Disease Neuroimaging InitiativeGiusti-RodriguezP, SullivanPF, HardyJ, FuAKY, LiY, IpNY (2019) Non-coding variability at the APOE locus contributes to the Alzheimer’s risk. Nat Commun10, 3310.
23.
BennettDA, SchneiderJA, ArvanitakisZ, WilsonRS (2012) Overview and findings from the religious orders study. Curr Alzheimer Res9, 628–645.
24.
BennettDA, SchneiderJA, BuchmanAS, BarnesLL, BoylePA, WilsonRS (2012) Overview and findings from the rush Memory and Aging Project. Curr Alzheimer Res9, 646–663.
25.
BesserL, KukullW, KnopmanDS, ChuiH, GalaskoD, WeintraubS, JichaG, CarlssonC, BurnsJ, QuinnJ, SweetRA, RascovskyK, TeylanM, BeeklyD, ThomasG, BollenbeckM, MonsellS, MockC, ZhouXH, ThomasN, RobichaudE, DeanM, HubbardJ, JackaM, Schwabe-FryK, WuJ, PhelpsC, MorrisJC; Neuropsychology Work Group, Directors, and Clinical Core leaders of the National Institute on Aging-funded US Alzheimer’s Disease Centers (2018) Version 3 of the National Alzheimer’s Coordinating Center’s Uniform Data Set. Alzheimer Dis Assoc Disord32, 351–358.
26.
MorrisJC, WeintraubS, ChuiHC, CummingsJ, DecarliC, FerrisS, FosterNL, GalaskoD, Graff-RadfordN, PeskindER, BeeklyD, RamosEM, KukullWA (2006) The Uniform Data Set (UDS): Clinical and cognitive variables and descriptive data from Alzheimer Disease Centers. Alzheimer Dis Assoc Disord20, 210–216.
27.
BennettDA, BuchmanAS, BoylePA, BarnesLL, WilsonRS, SchneiderJA (2018) Religious Orders Study and Rush Memory and Aging Project. J Alzheimers Dis64, S161–S189.
28.
McKhannGM, KnopmanDS, ChertkowH, HymanBT, JackCRJr, KawasCH, KlunkWE, KoroshetzWJ, ManlyJJ, MayeuxR, MohsRC, MorrisJC, RossorMN, ScheltensP, CarrilloMC, ThiesB, WeintraubS, PhelpsCH (2011) The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement7, 263–269.
29.
AlbertMS, DeKoskyST, DicksonD, DuboisB, FeldmanHH, FoxNC, GamstA, HoltzmanDM, JagustWJ, PetersenRC, SnyderPJ, CarrilloMC, ThiesB, PhelpsCH (2011) The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement7, 270–279.
30.
BennettDA, SchneiderJA, AggarwalNT, ArvanitakisZ, ShahRC, KellyJF, FoxJH, CochranEJ, ArendsD, TreinkmanAD, WilsonRS (2006) Decision rules guiding the clinical diagnosis of Alzheimer’s disease in two community-based cohort studies compared to standard practice in a clinic-based cohort study. Neuroepidemiology27, 169–176.
31.
WeintraubS, BesserL, DodgeHH, TeylanM, FerrisS, GoldsteinFC, GiordaniB, KramerJ, LoewensteinD, MarsonD, MungasD, SalmonD, Welsh-BohmerK, ZhouXH, ShirkSD, AtriA, KukullWA, PhelpsC, MorrisJC (2018) Version 3 of the Alzheimer Disease Centers’ Neuropsychological Test Battery in the Uniform Data Set (UDS). Alzheimer Dis Assoc Disord32, 10–17.
32.
WeintraubS, SalmonD, MercaldoN, FerrisS, Graff-RadfordNR, ChuiH, CummingsJ, DeCarliC, FosterNL, GalaskoD, PeskindE, DietrichW, BeeklyDL, KukullWA, MorrisJC (2009) The Alzheimer’s Disease Centers’ Uniform Data Set (UDS): The neuropsychologic test battery. Alzheimer Dis Assoc Disord23, 91–101.
33.
HymanBT, PhelpsCH, BeachTG, BigioEH, CairnsNJ, CarrilloMC, DicksonDW, DuyckaertsC, FroschMP, MasliahE, MirraSS, NelsonPT, SchneiderJA, ThalDR, ThiesB, TrojanowskiJQ, VintersHV, MontineTJ (2012) National Institute on Aging-Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease. Alzheimers Dement8, 1–13.
34.
WilsonRS, BieniasJL, Berry-KravisE, EvansDA, BennettDA (2002) The apolipoprotein E epsilon 2 allele and decline in episodic memory. J Neurol Neurosurg Psychiatry73, 672–677.
35.
StoneDJ, MolonyC, SuverC, SchadtEE, PotterWZ (2010) ApoE genotyping as a progression-rate biomarker in phase II disease-modification trials for Alzheimer’s disease. Pharmacogenomics J10, 161–164.
36.
YuL, BoyleP, SchneiderJA, SegawaE, WilsonRS, LeurgansS, BennettDA (2013) APOE epsilon4, Alzheimer’s disease pathology, cerebrovascular disease, and cognitive change over the years prior to death. Psychol Aging28, 1015–1023.
37.
ReasET, LaughlinGA, BergstromJ, Kritz-SilversteinD, Barrett-ConnorE, McEvoyLK (2019) Effects of APOE on cognitive aging in community-dwelling older adults. Neuropsychology33, 406–416.
MirraSS, HeymanA, McKeelD, SumiSM, CrainBJ, BrownleeLM, VogelFS, HughesJP, van BelleG, BergL (1991) The Consortium to Establish a Registry for Alzheimer’s Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer’s disease. Neurology41, 479–486.
RamananVK, CastilloAM, KnopmanDS, Graff-RadfordJ, LoweVJ, PetersenRC, JackCRJr, MielkeMM, VemuriP (2019) Association of apolipoprotein E varepsilon4, educational level, and sex with tau deposition and tau-mediated metabolic dysfunction in older adults. JAMA Netw Open2, e1913909.
42.
SafiehM, KorczynAD, MichaelsonDM (2019) ApoE4: An emerging therapeutic target for Alzheimer’s disease. BMC Med17, 64.
43.
KimJ, BasakJM, HoltzmanDM (2009) The role of apolipoprotein E in Alzheimer’s disease. Neuron63, 287–303.
44.
BlueEE, HorimotoA, MukherjeeS, WijsmanEM, ThorntonTA (2019) Local ancestry at APOE modifies Alzheimer’s disease risk in Caribbean Hispanics. Alzheimers Dement15, 1524–1532.
45.
PourhoseingholiMA, BaghestaniAR, VahediM (2012) How to control confounding effects by statistical analysis. Gastroenterol Hepatol Bed Bench5, 79–83.
46.
SteenlandK, GoldsteinFC, LeveyA, WhartonW (2016) A meta-analysis of Alzheimer’s disease incidence and prevalence comparing African-Americans and Caucasians. J Alzheimers Dis50, 71–76.
